Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abituzumab - Merck Serono

Next Previous
Search
Drug Profile

Abituzumab - Merck Serono

Alternative Names: Anti-CD51 antigen mAb; Anti-integrin alphaV mAb; DI 17E6; EMD525797

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EMD Serono; Merck Serono
  • Developer Merck Serono; SFJ Pharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Discontinued Ovarian cancer; Prostate cancer; Solid tumours; Systemic scleroderma

Most Recent Events

  • 19 Jul 2022 Phase-II clinical trials in Colorectal cancer in USA (IV) (SFJ Pharmaceuticals pipeline, July 2022)
  • 02 May 2018 Merck enters into a agreement with with SFJ Pharmaceuticals to develop abituzumab through a novel risk-sharing collaboration agreement
  • 11 Jan 2018 Merck and EMD Serono discontinues phase-II clinical trials in Systemic scleroderma in USA, Spain, United Kingdom, Poland, Italy, Israel, Canada, Australia, Argentina (IV) (NCT02745145)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top